Filter Results:
(1,343)
Show Results For
- All HBS Web
(1,343)
- People (4)
- News (315)
- Research (652)
- Multimedia (16)
- Faculty Publications (343)
Show Results For
- All HBS Web
(1,343)
- People (4)
- News (315)
- Research (652)
- Multimedia (16)
- Faculty Publications (343)
- June 2023 (Revised July 2024)
- Case
Biogen and the Aduhelm Melee
By: Amitabh Chandra and Lauren Gunasti
Alzheimer's Disease is a devastating condition affecting millions of Americans. At this time, there is no cure. In 2021, Biogen's Aduhelm (aducanumab) received FDA approval under the accelerated approval pathway after a controversial approval process.
This... View Details
This... View Details
Keywords: Health Testing and Trials; Governing Rules, Regulations, and Reforms; Valuation; Product Development; Pharmaceutical Industry
Chandra, Amitabh, and Lauren Gunasti. "Biogen and the Aduhelm Melee." Harvard Business School Case 623-046, June 2023. (Revised July 2024.)
- November 2009 (Revised March 2010)
- Case
Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story
By: Richard G. Hamermesh, Raju Kucherlapati and Rachel Gordon
In May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, developed to fight metastatic colorectal cancer, had been rejected. This was especially surprising news given that a similar rival drug had... View Details
Keywords: Entrepreneurship; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Marketing Strategy; Product Positioning; Genetics; Biotechnology Industry; Europe; United States
Hamermesh, Richard G., Raju Kucherlapati, and Rachel Gordon. "Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story." Harvard Business School Case 810-066, November 2009. (Revised March 2010.)
- 11 Dec 2012
- First Look
First Look: Dec. 11
of Health Care Reform Oberholzer-Gee, Felix, Raffaella Sadun, and Richard G. HamermeshHarvard Business School Case 711-403 Per the Patient Protection and Affordable Care Act (PPACA), which President Obama... View Details
Keywords: Sean Silverthorne
- February 2019 (Revised August 2019)
- Case
Maccabitech: The Promise of Israel's Healthcare Data
By: Scott Duke Kominers and Carin-Isabel Knoop
Dr. Varda Shalev bridges technology and medicine through Maccabitech, a "research and innovation wing" of Israel's Maccabi Healthcare Services (MHS) that partners with research institutions, pharmaceutical companies, and startups. Shalev hopes to scale Maccabitech's... View Details
Keywords: Big Data; Healthcare; Analytics and Data Science; Digital Platforms; Health Care and Treatment; Innovation and Invention; Research; Entrepreneurship; Risk Management; Israel
Kominers, Scott Duke, and Carin-Isabel Knoop. "Maccabitech: The Promise of Israel's Healthcare Data." Harvard Business School Case 819-032, February 2019. (Revised August 2019.)
- Web
Buy Now, Pay Later: The Secondary Credit Market
operating as an ordinary pawnshop. But it boasted interest rates that were one half to one third of the legal rate charged by independent pawnbrokers. 29 Reformers initially aimed to drive loan sharks out of business. In addition to the... View Details
- Web
Working with Professors at HBS - MBA
Business & Environment Career Change Career and Professional Development Case Method Clubs Curriculum Digital Entrepreneurship FIELD Financial Aid Health Care Instagram Takeover JD/MBA Leadership Letters to... View Details
- Web
My HBS Student Loan Story: John Cortines (MBA 2015) - MBA
Business & Environment Career Change Career and Professional Development Case Method Clubs Curriculum Digital Entrepreneurship FIELD Financial Aid Health Care Instagram Takeover JD/MBA Leadership Letters to... View Details
- Profile
Frank Spencer
know the details of the plan. You just have to be willing to participate with others in the work." "Real estate is the thread that's run through my career," adds Spencer, who most recently served as president of Cogdell Spencer Inc., a publicly traded... View Details
- Web
HBS Global Opportunity Fellowship: Making a Difference in Africa - MBA
Business & Environment Career Change Career and Professional Development Case Method Clubs Curriculum Digital Entrepreneurship FIELD Financial Aid Health Care Instagram Takeover JD/MBA Leadership Letters to... View Details
- Web
SEI25 Series: Misan Rewane, MBA 2013, CEO WAVE - MBA
Business & Environment Career Change Career and Professional Development Case Method Clubs Curriculum Digital Entrepreneurship FIELD Financial Aid Health Care Instagram Takeover JD/MBA Leadership Letters to... View Details
- Web
Finding the Confidence to Apply to HBS - MBA
Business & Environment Career Change Career and Professional Development Case Method Clubs Curriculum Digital Entrepreneurship FIELD Financial Aid Health Care Instagram Takeover JD/MBA Leadership Letters to... View Details
- Web
Being a Mom and a Founder at HBS - MBA
Business & Environment Career Change Career and Professional Development Case Method Clubs Curriculum Digital Entrepreneurship FIELD Financial Aid Health Care Instagram Takeover JD/MBA Leadership Letters to... View Details
- Web
Valuing an MBA: Beyond Dollars and “Sense" - MBA
Business & Environment Career Change Career and Professional Development Case Method Clubs Curriculum Digital Entrepreneurship FIELD Financial Aid Health Care Instagram Takeover JD/MBA Leadership Letters to... View Details
- August 2008 (Revised May 2009)
- Background Note
Note on Generic Drugs in the European Union
By: Robert C. Pozen and Elizabeth M. Leonard
Rules governing the introduction of generic drugs in U.S. and EU have some similarities but significant differences because of the Hatch-Waxman Act in the U.S. View Details
Keywords: Governing Rules, Regulations, and Reforms; Government Legislation; Health Care and Treatment; Trademarks; Brands and Branding; Pharmaceutical Industry; European Union; United States
Pozen, Robert C., and Elizabeth M. Leonard. "Note on Generic Drugs in the European Union." Harvard Business School Background Note 309-019, August 2008. (Revised May 2009.)
- August 2001
- Case
Scios, Inc.
Scios, filled with distinguished scientists and experienced managers, nevertheless fails to clear the FDA Phase III process for an important biotechnology drug. This case asks the students to analyze the social costs and benefits of the regulatory process. View Details
- Web
Research Links: Records of Railroad Companies & Personal Papers - Railroads and the Transformation of Capitalism | Harvard Business School
study of change in business structure and managerial organization. He wrote his dissertation on Henry Varnum Poor, a railroad journalist and economist (also his great-grandfather), which was published in 1956 as Henry Varnum Poor, Business Editor, Analyst, and View Details
- 2024
- Working Paper
Chimeric Antigen Receptor T-Cell Therapy—Living Drugs: Case Histories of Transformational Advances
By: Amar Bhidé and Srikant M. Datar
In 2017, the US Food and Drug Administration (FDA) approved an immunotherapeutic treatment, called CAR-T therapy, for two kinds of blood cancers—acute leukemia (ALL) and a lymphoma. We describe 1) how CAR-T works, 2) the foundational advances and discoveries, 3) the... View Details
Keywords: Immunotherapy; Health Care and Treatment; Innovation and Invention; Research and Development; Governing Rules, Regulations, and Reforms
Bhidé, Amar, and Srikant M. Datar. "Chimeric Antigen Receptor T-Cell Therapy—Living Drugs: Case Histories of Transformational Advances." Harvard Business School Working Paper, No. 21-035, August 2020. (Revised May 2024.)
- 01 Mar 2014
- News
Innovation: Crowdfunding College Costs
noted, Cordero started GradSave, an online college savings registry that makes it possible for family and friends to contribute directly to a child's 529 plan or savings account. Parents can send digital reminders of the account's... View Details
- 01 Jun 2017
- News
Developing Insight that Has Power in Practice
senior associate dean for research. “That’s the promise of HBS. The world’s problems are becoming increasingly complex and don’t lend themselves to one type of research. Our faculty employ constantly evolving methodologies to address topics of critical importance.” The... View Details
- 18 Feb 2014
- First Look
First Look: February 18
Most Successful CEOs Come from Within By: Bower, Joseph L. Abstract—The financial crisis of 2008 and the Great Recession caused a crisis of public confidence in business and American-style capitalism, with its focus on maximizing shareholder value. Corporate leaders... View Details
Keywords: Sean Silverthorne